Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer

Inclusion Criteria: * Histologically Confirmed Adenocarcinoma of the Gastroesophageal Junction (AEG I-III) or Gastric Adenocarcinoma (every T, N+ or T3/T4, Nx, M0) * Written Informed Consent * Age ≥ 18 Years * Expected operability * ECOG ≤ 2 * Exclusion of Peritoneal Metastasis * Adequate Hematological, Renal, Cardiac and Hepatic Function * Effective Contraception Exclusion Criteria: * Prior Chemotherapy or Radiotherapy of the Adenocarcinoma of the Gastroesophageal Junction (AEG I-III) or Gastric Adenocarcinoma * Not Histologically Confirmed Primary Tumor * Distant Metastasis, Local Relapse * Known Hypersensitivity for 5-Fluorouracil, Leucovorin, Oxaliplatin or Docetaxel * Known Dihydropyrimidin-Dehydrogenase (DPD) - Deficiency * Peripheral Polyneuropathy ≥ Grade II (NCI-CTCAE, Version 3.0) * Myocardial Infarction in the last 3 Months, Cardiac Insufficiency Grade II-IV (NYHA) * Severe Comorbidity or Acute Infections * Pregnancy or Breast Feeding * Insufficient Contraception * Participation in another Clinical Trial (Simultaneously or 30 Days Prior to Enrollment) * Malignancy \<5 years (except: Carcinoma In Situ of the Cervix Uteri or Adequately Treated Basalioma of the Skin) * Lack of Legal Capacity